|
|
|
|
|
|
NOT AVAILABLE IN THE US |
Seeplex® MTB/BCG ACE Detection is designed for the identification of Mycobacterium tuberculosis (MTB), and for the discrimination of M. bovis BCG (BCG) in clinical samples including sputum, body fluid, bronchial washing, urine, stool, CSF, and bone marrow aspiration.
Seeplex® MTB/BCG ACE Detection is made not only to test for tuberculosis but also to discriminate BCG
simultaneously with single PCR by designing primers using region of difference (RD) 1 gene. RD1 gene is present in all virulent Mycobacterium tuberculosis strains; however, attenuated Mycobacterium bovis BCG vaccine strain does not contain this gene1). By differentiating MTB from M. bovis BCG, an appropriate drug regimen is prescribed resulting in prevention of administering an unnecessary antituberculosis drug and reducing the incidence of drug resistance.
1) Daugelat S et al. Microbes Infect. 2003 Oct;5(12):1082-95 |
 |
| A. |
Multiplex PCR with high sensitivity and specificity by applying DPO™ (Dual Priming Oligonucleotide) technology |
| B. |
Applicable for Auto-capillary Electrophoresis device |
| |
PCR amplicons are separated and analyzed automatically; consequently, rapid and easy interpretation of the results is possible. |
| C. |
Contamination Prevention Syste |
| |
One-time PCR reduces the carryover contamination risk, and 8-MOP, which is included in product, eliminates the contamination risk from PCR. |
| D. |
Accurate system for interpretation of results |
| |
Internal Control and Positive Control are included in product. |
|
 |
- MTB
|
|
- M. bovis BCG (BCG)
|
 |
- Sputum
- Body fluid
- Bronchial washing
- Urine
- Stool
|
|
- CSF
- Blood
- Bone marrow aspiration
- Fresh tissue
|
|
 |
 |
ScreenTape®
System
(Agilent
Technologies)
 |
 |
MCE®-202
MultiNA
SHIMADZU
|
|
|
|
 |
| Product |
Cat. No. |
Size |
| Seeplex® MTB/BCG ACE Detection |
TB3110Y |
50 rxns |
|
|
|
|
|
|
